CA2999177A1 - Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment - Google Patents

Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment Download PDF

Info

Publication number
CA2999177A1
CA2999177A1 CA2999177A CA2999177A CA2999177A1 CA 2999177 A1 CA2999177 A1 CA 2999177A1 CA 2999177 A CA2999177 A CA 2999177A CA 2999177 A CA2999177 A CA 2999177A CA 2999177 A1 CA2999177 A1 CA 2999177A1
Authority
CA
Canada
Prior art keywords
compound
cells
human
compounds
sphingolipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2999177A
Other languages
English (en)
French (fr)
Inventor
Aimee EDINGER
Stephen Hanessian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite De Montreal
University of California, San Diego
Original Assignee
Universite De Montreal
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite De Montreal, University of California, San Diego filed Critical Universite De Montreal
Publication of CA2999177A1 publication Critical patent/CA2999177A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2999177A 2015-09-24 2016-09-26 Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment Pending CA2999177A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562232377P 2015-09-24 2015-09-24
US62/232,377 2015-09-24
PCT/US2016/053815 WO2017053990A1 (en) 2015-09-24 2016-09-26 Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment

Publications (1)

Publication Number Publication Date
CA2999177A1 true CA2999177A1 (en) 2017-03-30

Family

ID=58387539

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2999177A Pending CA2999177A1 (en) 2015-09-24 2016-09-26 Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment

Country Status (7)

Country Link
US (3) US10995068B2 (enExample)
EP (1) EP3352753A4 (enExample)
JP (1) JP6853539B2 (enExample)
CN (1) CN108366990B (enExample)
CA (1) CA2999177A1 (enExample)
MX (1) MX394367B (enExample)
WO (1) WO2017053990A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015009731A2 (en) 2013-07-15 2015-01-22 The Regents Of The University Of California Azacyclic constrained analogs of fty720
EP3352753A4 (en) 2015-09-24 2019-03-13 The Regents of The University of California SYNTHETIC SPHINGOLIPIDE-SIMILAR MOLECULES, MEDICAMENTS, METHODS FOR THEIR SYNTHESIS AND TREATMENT PROCEDURES
MA50532A (fr) 2017-11-03 2020-09-09 Univ Virginia Patent Foundation Compositions et méthodes pour le traitement de cancers
US20210261583A1 (en) * 2018-06-14 2021-08-26 The Regents Of The University Of California Synthetic Cytotoxic Molecules, Drugs, Methods of Their Synthesis and Methods of Treatment
WO2021062168A1 (en) * 2019-09-25 2021-04-01 The Regents Of The University Of California Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment
CA3158256A1 (en) * 2019-11-13 2021-05-20 Aimee EDINGER Drug formulations and methods of treatment for metabolic disorders
US12486274B2 (en) 2020-01-13 2025-12-02 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
CN116617221B (zh) * 2022-02-11 2025-06-17 复旦大学 Trpml1特异性小分子激动剂ml-sa1在制药中的用途

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3840523A (en) 1973-04-25 1974-10-08 Richardson Merrell Inc Tricyclic arylalkylene lactamimides
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
EP0366685B1 (en) 1987-06-24 1994-10-19 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
JPH0874B2 (ja) 1990-07-27 1996-01-10 アイシス・ファーマシューティカルス・インコーポレーテッド 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5948903A (en) 1991-01-11 1999-09-07 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
EP0637965B1 (en) 1991-11-26 2002-10-16 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP1015469B2 (en) 1997-09-12 2015-11-18 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US20030158403A1 (en) 2001-07-03 2003-08-21 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US20030175906A1 (en) 2001-07-03 2003-09-18 Muthiah Manoharan Nuclease resistant chimeric oligonucleotides
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
WO2005027962A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
WO2005041899A2 (en) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
WO2005056577A2 (en) 2003-12-05 2005-06-23 The Regents Of The University Of California Peptide inhibitors of hiv
US20070258970A1 (en) 2003-12-09 2007-11-08 Robert Blumenthal Methods for Inhibiting Hiv and Other Viral Infections by Modulating Ceramide Metabolism
WO2005122379A2 (en) 2004-05-27 2005-12-22 The Regents Of The University Of California Alpha-4 beta-1 integrin ligands for imaging and therapy
BRPI0514316A (pt) 2004-08-13 2008-06-10 Praecis Pharm Inc métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p)
EP1950198B1 (en) 2005-10-31 2014-08-06 Toray Fine Chemicals Co., Ltd. Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
DE602007009487D1 (de) 2006-01-27 2010-11-11 Isis Pharmaceutical Inc 6-modifizierte bicyclische nukleinsäureanaloga
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
ES2414205T3 (es) 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
US7968733B2 (en) 2006-06-06 2011-06-28 Gifu University Pyrrolidine analogue for preventing neurogenic pain and method for production thereof
US20100016260A1 (en) 2006-08-01 2010-01-21 Praecis Pharmaceuticals Incorporated Agonists of sphingosine-1 phosphate receptor (slp)
CN101506164A (zh) 2006-08-23 2009-08-12 辉瑞产品公司 哌啶衍生物
BRPI0720478A2 (pt) 2006-12-21 2014-01-14 Abbott Laboratoires Compostos agonistas e antagonistas do receptor esfingosina-1-fosfato
WO2008097819A2 (en) 2007-02-05 2008-08-14 Smithkline Beecham Corporation Chemical compounds
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
DK2170917T3 (da) 2007-05-30 2012-10-08 Isis Pharmaceuticals Inc N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
EP2188298B1 (en) 2007-08-15 2013-09-18 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
WO2009053481A1 (en) 2007-10-25 2009-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for modulating nk and t cell trafficking
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
EP2265627A2 (en) 2008-02-07 2010-12-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2009106599A2 (en) 2008-02-29 2009-09-03 Novartis Ag Substituted piperidines as therapeutic compounds
GB0811451D0 (en) 2008-06-20 2008-07-30 Syngenta Participations Ag Novel microbiocides
UA106591C2 (uk) 2008-07-23 2014-09-25 Тамара Алєксандровна Віткалова Спосіб лікування гепатиту с з використанням інтерферону та інтерлейкіну-1
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
WO2011133876A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US8309768B2 (en) * 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
WO2014118556A2 (en) 2013-01-31 2014-08-07 Research Foundation Of The City University Of New York Selective inhibitors and allosteric activators of sphingosine kinase
TWI613182B (zh) 2013-02-21 2018-02-01 必治妥美雅史谷比公司 雙環化合物
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
WO2015009731A2 (en) * 2013-07-15 2015-01-22 The Regents Of The University Of California Azacyclic constrained analogs of fty720
WO2015106128A2 (en) 2014-01-09 2015-07-16 Alnylam Pharmaceuticals, Inc. MODIFIED RNAi AGENTS
US20180078561A1 (en) 2015-03-31 2018-03-22 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
CN108779073A (zh) 2015-06-23 2018-11-09 凯斯西储大学 用于治疗癌症的组合物和方法
EP3352753A4 (en) 2015-09-24 2019-03-13 The Regents of The University of California SYNTHETIC SPHINGOLIPIDE-SIMILAR MOLECULES, MEDICAMENTS, METHODS FOR THEIR SYNTHESIS AND TREATMENT PROCEDURES
US20210261583A1 (en) 2018-06-14 2021-08-26 The Regents Of The University Of California Synthetic Cytotoxic Molecules, Drugs, Methods of Their Synthesis and Methods of Treatment
WO2021062168A1 (en) 2019-09-25 2021-04-01 The Regents Of The University Of California Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment
CA3158256A1 (en) 2019-11-13 2021-05-20 Aimee EDINGER Drug formulations and methods of treatment for metabolic disorders
US20240277740A1 (en) 2020-05-16 2024-08-22 Viratides, Llc Treatment of known and unknown viral infection with lipid agents
WO2022094615A1 (en) 2020-10-29 2022-05-05 The Regents Of The University Of California Compounds and methods for increased antisense activity
WO2022133494A1 (en) 2020-12-17 2022-06-23 The Regents Of The University Of California Antiviral compounds and applications thereof

Also Published As

Publication number Publication date
HK1259078A1 (zh) 2019-11-22
MX394367B (es) 2025-03-24
US20230122855A1 (en) 2023-04-20
US20180265464A1 (en) 2018-09-20
EP3352753A1 (en) 2018-08-01
CN108366990A (zh) 2018-08-03
MX2018003685A (es) 2018-08-15
JP6853539B2 (ja) 2021-03-31
US10995068B2 (en) 2021-05-04
WO2017053990A1 (en) 2017-03-30
US11479530B2 (en) 2022-10-25
CN108366990B (zh) 2021-09-03
US20210261504A1 (en) 2021-08-26
JP2018534256A (ja) 2018-11-22
EP3352753A4 (en) 2019-03-13
US11999693B2 (en) 2024-06-04

Similar Documents

Publication Publication Date Title
US11479530B2 (en) Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
US9447088B2 (en) Compositions and methods for treatment of cancer
TW201740979A (zh) 熱休克蛋白（ｈｓｐ）９０抑制劑藥物共軛物
JP6862404B2 (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
US8716307B2 (en) Combination antineoplastic therapy
JP2018062526A (ja) ｍＴＯＲ経路関連疾患を治療するための化合物
JP6617702B2 (ja) Ｆｔｙ７２０のアザサイクリック拘束アナログ
US11352382B2 (en) Mito-lonidamine, compositions and methods of use
TWI557128B (zh) 組成物在製備用於預防或治療非小細胞肺癌之藥物之用途
JP2025028945A (ja) ビスホスホネート連結化合物
US20100041691A1 (en) Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein
HK1259078B (en) Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
US11426371B2 (en) Compositions and methods for treating cancer
JP2004534751A (ja) 応力で活性化する蛋白質キナーゼの阻害剤を用いて痛みを治療および予防する新規な方法
AU2018101501A4 (en) Method of treating cancer
US20140045883A1 (en) Ack1 kinase inhibition to treat triple negative breast cancer
JP2026516175A (ja) 微小血管機能障害および関連疾患の診断および治療のための組成物および方法
HK40124880A (en) A novel small molecule kras inhibitor: drugging undruggable targets for cancer therapeutics
US20140235581A1 (en) Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210924